-
SpeichernDas Eingabefeld wird
gespeichert wenn Sie das Feld
verlassen oder hier klicken.Börse London Stock ExchangeISIN GB0009252882-
GlaxosmithklineBörse London Stock ExchangeISIN GB0009252882Symbol GSK
-
GlaxosmithklineBörse Börse FrankfurtISIN GB0009252882 WKN: 940561Symbol GS7
-
GlaxosmithklineBörse Börse BerlinSymbol GS7A
-
GLAXOSMITHKLINE PLC-SPON ADRBörse Börse FrankfurtSymbol GS7A
-
GlaxosmithklineBörse Börse StuttgartSymbol GS7A
-
GlaxosmithklineBörse Börse MünchenSymbol GS7A
-
GlaxosmithklineBörse Gettex System der Börse MünchenSymbol GS7A
-
GLAXOSMITHKLINE PLCBörse Tradegate System der Deutsche Börse AG (60%)Symbol GS7
-
GLAXOSMITHKLINE PLCBörse Börse BerlinSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Quotrix System der Börse DüsseldorfSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Börse HamburgSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Börse DüsseldorfSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Börse MünchenSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Börse StuttgartSymbol GS7
-
GLAXOSMITHKLINE PLCBörse Gettex System der Börse MünchenSymbol GS7
-
GlaxosmithklineBörse Tradegate System der Deutsche Börse AG (60%)Symbol GS7A
-
GlaxosmithklineBörse Börse HamburgSymbol GS7A
-
GlaxosmithklineBörse Quotrix System der Börse DüsseldorfSymbol GS7A
-
GlaxosmithklineBörse Börse DüsseldorfSymbol GS7A
-
GlaxosmithklineBörse NYSE New York Stock ExchangeISIN GB0009252882 WKN: 940561Symbol GSK
-
GlaxosmithklineBörse Amerikanscher Freiverkehr OTC oder "Pink Sheets"Symbol GSK.LN
-
GlaxoSmithKline PLC ADRBörse NYSE New York Stock ExchangeISIN US37733W1053 WKN: 940610Symbol GSK
-
GLAXOSMITHKLINE PHARMACEUTICALBörse BSE
-
GlaxosmithklineBörse Freiverkehr OTC
-
Symbol GS7
-
Die einen sagen so, die anderen so... Es gibt 3 Datenquellen:
93.879.525.376 oder 82.199.000.000 oder 81.582.338.640
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
94.066 oder 90.096 Mitarbeiter
Die einen sagen so, die anderen so... Es gibt 2 Datenquellen:
13.04 oder 18.9
Zahlte zuletzt am 20.05.2021 eine Dividende von 19 . Seit damals wurde keine Dividende mehr ausgeschüttet Übersicht
Glaxosmithkline läuft ähnlich wie der DAX (1.29 %) vom 05.07.2021 bis 10.09.2021
Die letzten Quartalsergebnisse Erwarteter Gewinn je Aktie beim aktuellen Wert von 1478,4 GBp +0,73%
Aktionärsstruktur der GlaxoSmithKline plc
Portrait der Glaxosmithkline Aktie
Das Unternehmen GlaxoSmithKline plc aus Großbritannien beschäftigt 92.081 Mitarbeiter und ist in den Bereichen Chemie & Pharma, Biotechnologie & Pharmazeutika, Pharma tätig.
Die Glaxosmithkline Aktie hat inklusive der Dividendenausschüttungen seit dem 05.07.2021 eine Gesamtrendite von 0% erwirtschaftet
Das Unternehmen GlaxoSmithKline plc ist in mehr als 78 ETFs enthalten und somit ein eher allgemein bekannter Wert. Der Spitzenreiter iShares STOXX Europe Select Dividend 30 UCITS ETF (DE) gewichtet Glaxosmithkline mit 6,17% im ETF.
Es ist auch möglich über Anleihen zu investieren. Hier findest du alle Glaxosmithkline Anleihen auf einen Blick.
Entdecke die 6 ETFs in denen GlaxoSmithKline plc am höchsten gewichtet ist Insgesamt in 78 ETFs enthalten
Dir gefallen die Informationen zu Glaxosmithkline?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne gerne ein kostenloses und unverbindliches Depot bei der ING Diba. Ich erhalte 20 wenn du daraufhin dann zum Beispiel einen Aktien-Sparplan anlegst oder etwas kaufst:
Dir gefallen die Informationen zu Glaxosmithkline?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein kostenloses und unverbindliches Depot bei Trade Republic mit der Möglichkeit kostenlos Aktien zu besparen. Wenn du das über meinen Link machst, bekommst du und ich bei deinem ersten Wertpapierkauf 15 von Trade Republic geschenkt:
Dir gefallen die Informationen zu Glaxosmithkline?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn du meine Arbeit unterstützen möchtest, dann eröffne ein kostenloses und unverbindliches Depot bei BUX Zero mit der Möglichkeit kostenlos US-Aktien und für einen Euro viele weitere Aktien aus Deutschland, Belgien, Niederlande, sterreich oder UK zu kaufen. Wenn du das über meinen Link machst, bekommen wir beide eine gratis Aktie geschenkt:
Dir gefallen die Informationen zu Glaxosmithkline?
Galue bleibt auch in Zukunft kostenfrei und ungesponsort. Wenn Ihr meine Arbeit unterstützen möchtet, dann eröffnet gerne ein mindestens 3 Jahre lang kostenloses Depot bei der comdirect. Wenn du das über diesen Link machst unterstützt du auch meine Tochter Zoe, da es Ihr Juniordepot ist. Sie erhält 20 und bei einem aktiven ETF- oder Aktien-Sparplan bleibt dein Depot auch danach kostenfrei:
238 News & Informationen zur Glaxosmithkline Aktie
Unilever : Appointment of Non-Executive Director (Form 6-K)
Appointment of Non-Executive Director
London, 21 July 2021 – Unilever PLC today announces that Adrian Hennah has been appointed as a Non-Executive Director of… | July 21, 2021
Global Anti-Inflammatory Therapeutics Market to Reach $125.55 Billion by 2028: AMR
Rise in prevalence of autoimmune diseases and chronic respiratory conditions, advent of new drugs, and surge in adoption rate of anti-inflammatory drugs…
What’s happening with the GSK share price?
The GSK share price seems to be going nowhere ahead of the company's big split. I do like GSK, but should I buy or should I wait?
Concorde Asset Management, LLC Buys KKR Inc, Orange SA, British American Tobacco PLC, Sells GrowGeneration Corp, iShares U.S. Medical Devices ETF, iShares iBoxx USD Investment Grade Corporate Bond
GuruFocus Article or News written by insider and the topic is about:
Sanofi, GlaxoSmithKline COVID-19 shot undergoes real time review in Europe (NYSE:GSK)
The European Medicines Agency ((EMA)) has started the rolling review of the experimental COVID-19 vaccine developed by Sanofi (SNY) and GlaxoSmithKline (GSK), the regulator said…
Global Monoclonal Antibodies Market is Expected to Reach $390.58 Billion by 2030: Says AMR
Increase in prevalence of various cancer types, rise in demand for cost-efficient biosimilar monoclonal antibodies, and upsurge in likelihood of epidemic…
GlaxoSmithKline : GSK Says ViiV Healthcare Study Shows New Long-Acting HIV Regimen Cabenuva Can Be Used In US Healthcare Practices
GlaxoSmithKline PLC:
* GSK-VIIV HEALTHCARE STUDY SHOWS NEW LONG-ACTING HIV
REGIMEN
CABENUVA CAN BE USED IN BROAD RANGE OF US HEALTHCARE PRACTICES,
EVEN DURING COVID-19
Source text for… | July 17, 2021
GlaxoSmithKline : ViiV Healthcare study shows new long-acting HIV regimen Cabenuva (cabotegravir/rilpivirine) can be successfully implemented in broad range of US healthcare practices, even during COV
For media and investors only
Issued:London, UK
Healthcare teams from a wide variety of US HIV clinics reported that optimal implementation of… | July 17, 2021
Blitz-Depot – Das erstes Halbjahr 2021
Rückblick und Auswertung: Das Blitz-Depot für Jedermann und Aktienliebhaber in der Retrospektive von Januar bis Juni 2021.
GlaxoSmithKline : GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease (Form 6-K)
GSK announces positive headline results from five Phase 3 studies of daprodustat for patients with anaemia due to chronic kidney disease
Full results to be presented at a… | July 16, 2021
GSK seeks to expand England R&D facility with new $550-million plan By Reuters
GSK seeks to expand England R&D facility with new $550-million plan
Norway Savings Bank Buys iShares MSCI USA Equal Weighted ETF, iShares U.S. Preferred Stock, NVIDIA Corp, Sells iShares MSCI Pacific ex Japan ETF, GlaxoSmithKline PLC, International Business Machines C
GuruFocus Article or News written by insider and the topic is about:
Global $140 Bn Over the Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
/PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products, Vitamins, Mineral, and…
Global $140 Bn Over The Counter (OTC) Drugs Markets, Forecast & Opportunities, 2025
DUBLIN, July 15, 2021 /PRNewswire/ — The “Global Over the Counter (OTC) Drugs Market, By Product (Cough, Cold, and Flu, Analgesics, Dermatology Products,
GlaxoSmithKline To Spin-Off Consumer Healthcare Business By Mid-2022
The company operates in three major business segments, Pharmaceuticals, Vaccines and Consumer Healthcare.
Report 2021, Influenza Vaccine Market Is Projected to Reach USD 10.73 Billion at CAGR of 7.4%
Influenza Vaccine Market Key Players are GlaxoSmithKline plc. (U.K, Europe), Sanofi S.A (France, Europe), AstraZeneca (Cambridge, United Kingdom), Seqirus…
As Moderna's Market Cap Nears $100-Billion, How Risky Is The Stock?
Stocks Analysis by Investing.com (Haris Anwar/Investing.com) covering: Gilead Sciences Inc, Pfizer Inc, Alexion Pharmaceuticals Inc, Sanofi ADR. Read Investing.com (Haris Anwar/Investing.com)'s latest article on Investing.com
10 Best Psychedelic Stocks to Buy Now
In this article, we discuss the 10 best psychedelic stocks to buy now. If you want to skip our detailed analysis of these stocks, go directly to the 5…
Protein Supplements Market Size Worth USD 24,004.8 Million by 2025 at 7.5% CAGR – Report by Market Research Future (MRFR)
Protein Supplements Market Insights and Industry Analysis by Source (Plant, Animal and others), Form (Powder, Liquid, Bar and others), Distribution Channel…
Global Generic Drugs Market To Reach $507.8 Billion By 2026
SAN FRANCISCO, July 14, 2021 /PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today
Global Generic Drugs Market to Reach $507.8 Billion by 2026
/PRNewswire/ — A new market study published by Global Industry Analysts Inc., (GIA) the premier market research company, today released its report titled…
Startup Genexa Raises $60 Million From Venture-Capital Firms and Celebrities, Including Gwyneth Paltrow
The maker of over-the-counter drugs is valued at roughly $200 million and is the latest to capitalize on the so-called clean-health and wellness trend.
Central Nervous System Disorders Therapeutics Market |Type and Geography| Forecast and Analysis 2021-2025|Technavio
/PRNewswire/ — Technavio has been monitoring the Center Nervous System Disorder Therapeutics Market and the market size is expected to reach a value of USD 24….
U.S. OTC Drugs Market Size to Reach Revenues USD 43.18 Billion by 2026
/PRNewswire/ — In-depth analysis and data-driven insights on the impact of COVID-19 included in this U.S. OTC drugs market report. The U.S. OTC drugs market…
Precision Medicine Market Size Worth USD 126.14 Billion by 2025 at 12.48% CAGR – Report by Market Research Future (MRFR)
Precision Medicine Market Insights and Industry Analysis by Therapeutics (Cancer/Oncology, Cardiovascular Disease (CVD), Infectious Diseases, Central…
Valuation in Geriatric Medicines Market to Reach US$ 1142.8 Bn by 2027, Use in Managing Cardiovascular Diseases Spurs Growth: TMR
/PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some emerging economies and developed…
Valuation In Geriatric Medicines Market To Reach US$ 1142.8 Bn By 2027, Use In Managing Cardiovascular Diseases Spurs Growth: TMR
ALBANY, N.Y., July 12, 2021 /PRNewswire/ — Geriatrics care has made enormous strides over the past few decades. Rapidly aging populations notably in some
Is the GSK share price a bargain at £14.35?
The GSK share price is little changed since last month's important investor update. Has G A Chester changed his positive pre-update view of the stock.
The Week Ahead In Biotech: Adcom Test Awaits FibroGen, Data Readouts, IPOs In The Mix
Biopharma stocks closed the holiday-shortened week lower amid a lack of any significant news flow. On the drug approval front, Provention Bio, In…
The Curious Case Of Elliott Advisors And GSK: Are Activist Investors What They Used To Be?
Elliott Advisors supports GSK's plans to split into two companies and has made five recommendations. One is that a refreshed board do an internal and external search for the CEO of New GSK. Many are interpreting this as an attack on CEO Emma Walmsley. It is not. It is just good corporate governance.
Investing Beyond the U.S. Borders
Investing abroad poses risks, but can also help you diversify. Discover ways to invest in foreign stocks.
Active Pharmaceutical Ingredients Market Worth USD 312 Billion by 2028 at 6.2% CAGR – Report by Market Research Future (MRFR)
Active Pharmaceutical Ingredients Market Insights and Industry Analysis by Type of Synthesis (Biotech and Synthetic), By Molecules (Large Molecule and…
Global Stress Management Market Size to Grow at a CAGR of 3.5% from 2021 to 2030
The global stress management market reached USD 18,600.9 million in 2020 and is projected to grow at a CAGR of 3.5% during the forecast period. Based on…
Global Stress Management Market Size to Grow at a CAGR of 3.5% from 2021 to 2030
The global stress management market reached USD 18,600.9 million in 2020 and is projected to grow at a CAGR of 3.5% during the forecast period. Based on…
Global Stress Management Market Size to Grow at a CAGR of 3.5% from 2021 to 2030
The global stress management market reached USD 18,600.9 million in 2020 and is projected to grow at a CAGR of 3.5% during the forecast period. Based on…
Global Stress Management Market Size to Grow at a CAGR of 3.5% from 2021 to 2030
The global stress management market reached USD 18,600.9 million in 2020 and is projected to grow at a CAGR of 3.5% during the forecast period. Based on…
Cullinan Associates Inc Buys Apple Inc, Lowe's Inc, Best Buy Co Inc, Sells Walmart Inc, Eaton Corp PLC, CME Group Inc
GuruFocus Article or News written by insider and the topic is about:
After the GSK share price leaps 21% in 4 months, I’m thinking about selling
Since its late-February low, the GSK share price has jumped more than a fifth. Four months on, is it time for me to sell up to seek higher returns?
A Look Into GlaxoSmithKline's Price Over Earnings
Looking into the current session, GlaxoSmithKline Inc. (NYSE:GSK) is trading at $39.92, after a 0.80% drop. Over the past month, the stock decreased …
Sanofi and GlaxoSmithKline granted Indian approval for COVID-19 vaccine trial (NYSE:GSK)
Indian regulators have cleared a late-stage clinical trial for the experimental COVID-19 vaccine developed by Sanofi (SNY) and GlaxoSmithKline (GSK).In May, the two companies started…